Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — Investor Presentation (September 2018)
22 slides from Halozyme Therapeutics's investor presentation, Sep 5, 2018
Slide 1: Building a Premier Oncology Biotech
Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such statements include possible activity, benefits and attr
Slide 3: Two Engines for Growth
Two Engines for Growth Proven ‘IV to Sub Q’ Partnering Platform Late Stage Oncology Asset ENHANZE® PEGPH20 Fast-growing Revenue Stream Near-term Phase 3 Data in Potential ~$1B Global Pancreas Indication $1B annual Royalty Revenue Potential ~$1B annual Royalty Revenue Projection in 2027 ~30% CAGR pro
Slide 4: ENHANZE
ENHANZE®
Slide 5: Potential for Competitive Differentiation
Potential for Competitive Differentiation New Intellectual Property and Exclusivity Changing U.S. Reimbursement and Care Landscape Reduced Treatment Burden and Healthcare Costs ENHANZE® Offers Four Potential Paths for Differentiation and Value Creation for Partners 1 2 3 4
Slide 6: ENHANZE High-Growth Potential Business Model
Number of Targets 11 Upfront $105M Milestones/ target $160M Royalties Mid-single digit average across all agreements ENHANZE ® High-Growth Potential Business Model 8 Agreements signed: Roche (Genentech), Baxalta, Pfizer, Janssen, Eli Lilly, Abbvie BMS and Alexion 50 Potential Targets in total ~$1B L
Slide 7: ENHANZE Target Overview
ENHANZE® Target Overview 50% of all targets under contract are nominated Number of targets accessible through signed contracts 50 Nominated 25 Open 22 Discontinued 3 ~50% of nominated targets are marketed or will be in development in 2018 Marketed: 3 In development 2018: 9
Slide 8: Robust ENHANZE Royalty Growth
Robust ENHANZE® Royalty Growth U.S. Launch Ex-U.S. Launch Ex-U.S. Launch Ex-U.S. Launch U.S. Launch1 1Quarterly reporting lag in 2017; revenue reflected in 2018 Guidance: Projected +25-30% Growth
Slide 9: ENHANZE: ~$1B Royalty Revenue Potential in 2027
2017 ENHANZE®: ~$1B Royalty Revenue Potential in 2027 ~$1 Billion 2027 30%+ CAGR Projection based on approved products and assumes global approval and launches for 7 additional products in multiple indications. Includes projections for subcutaneous versions of targets not currently approved or comme
Slide 10: ENHANZE Development Pipeline
Phase 1 ENHANZE® Development Pipeline Phase 3 ALXN1210 CD73 Undisclosed Partner Product/Target Undisclosed Undisclosed Undisclosed Undisclosed Perjeta/ Herceptin FDC Start Q3 2018 Start 2H 2018 Start 2H 2018 Start Q3 2018 Start Q3 2018 Phase 3 Study Ongoing Started 2017 Started 1Q 18 4 Phase 3 Studi
Slide 11: Strategy To Accelerate ENHANZE Growth
Strategy To Accelerate ENHANZE ® Growth Advance Current Partner Targets … … And Sign New Partner Agreements Currently Partnered with 8 of the World’s 50 Largest Drug Companies ENHANZE Potential in Oncology, Rare Diseases, Blood Disorders, CNS… More Approvals Lead to More Inquiries Current Plan: 9 Ta
Slide 12: PEGPH20
PEGPH20
Slide 13: Retrospective Evaluation of Pancreatic Cancer Survival
Retrospective Evaluation of Pancreatic Cancer Survival in ~50 Patients1 HA-Low Median Survival: 24.3 months H.R. 2.6 p=0.037 HA-High Median Survival: 9.3 months 1 Whatcott et al: Clin Cancer Res 2015, 21:3561-3568. HA staining by HABP. Scoring algorithm assessed percent staining and intensity. Tumor
Slide 14: PEGPH20 Targets Hyaluronan in the Tumor Microenvironment
PEGPH20 Targets Hyaluronan (HA) in the Tumor Microenvironment PEGPH20 In HA-High Tumor Animal Models, Removal of HA by PEGPH20 Demonstrated to: Decrease intratumoral pressure Decompress vasculature Increase perfusion Increase access for therapeutics Increase access for immune cells
Slide 15: PEGPH20 Targets and Degrades Hyaluronan
1 Provenzano, et al. Cancer Cell. 2012,21(3):418. PEGPH20 Targets and Degrades Hyaluronan Before PEGPH201 Hard Fibrotic Hypovascular MPA#1 + Gemcitabine After PEGPH201 Soft Cellular Hypervascular
Slide 16: ~$1B Potential Opportunity in Pancreas Cancer
1 SEER 18 2006-2012, Globocan 2012, DRG Epidemiology data. 2 Halozyme estimates for HA-High %. 3 DRG Epidemiology data, Halozyme internal estimates. ~$1B Potential Opportunity in Pancreas Cancer Annual Diagnosed Metastatic Pancreatic Ductal Adenocarcinoma (PDA) U.S. and EU 51 Estimated Number of HA-
Slide 17: PEGPH20 Pancreas Cancer Program De-risking Event Timeline
PEGPH20 Pancreas Cancer Program De-risking Event Timeline 2013 HALO-202, Phase 2 randomized, controlled study initiated PEGPH20 plus Abraxane (A)and gemcitabine (G) versus AG 2016 Stage 1 HALO-202 data utilized to establish Companion Diagnostic algorithm and cutpoint Initiated Phase 3 HALO-301 study
Slide 18: Encouraging Data with PEGPH20 plus AG
Encouraging Data with PEGPH20 plus AG Dr. Kenneth Yu, Investigator Trial presented at ASCO 2018 All patients received PEGPH20, Abraxane, gemcitabine and rivaroxaban Primary endpoint: rate of TE events. No Grade 3/4 events reported Secondary endpoints: 80 60 40 20 0 –20 –40 –60 –80 –100 Change (%) 73
Slide 19: HALO-301: Pancreas Cancer
HALO-301: Pancreas Cancer Randomized (2:1 PAG:AG), double-blind, placebo-controlled, global Projected to achieve target number of PFS events between December 2018 and February 2019, triggering final data collection, cleaning and interim analysis PEGPH20 + ABRAXANE® + gemcitabine (PAG) ABRAXANE® + ge
Slide 20: Pan-tumor Testing of PEGPH20
Tumor Combination Eribulin (Halaven®) Eisai led Pembrolizumab (Keytruda®) Atezolizumab (Tecentriq®) Roche Atezolizumab (Tecentriq) Breast Cancer Gastric Cancer, NSCLC Pancreas Cancer, Gastric Cancer Gall Bladder Cancer, Cholangiocarcinoma Chemotherapy Checkpoint Inhibitors Enrollment Closed Enrollme
Slide 21: Halozyme Outlook
Halozyme Outlook ENHANZE® PEGPH20 Near-term Phase 3 Data in ~$1B potential Global Pancreas Indication ~30% CAGR in Projected Royalty Revenue to 2027 Pan-tumor Data in Breast Cancer and Pancreas Cancer at ESMO FINANCIAL $310-320M Projected YE 2018 Cash Potential ~$1B annual Royalty Revenue Projection
Slide 22: Building a Premier Oncology Biotech
Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018
Halozyme Therapeutics — Investor Presentation (September 2018) on 6ix